Get the SPI Wire

Endovia Health Sciences, Inc.

NYSE:EDVA
Annual Meeting

of Shareholders

MEETING DATE

12/07/2026
DEF 14A FILED
11/02/2026
PUBLISHED
11/02/2026 9:26 pm
TIME TO PUBLISH
11/04/2026
METHODOLOGY
approve
EXCHANGE NYSE:EDVA · CUSIP 13754P105 · CLASS common stock · CIK 0001553788

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
0
AGAINST
0
WITHHOLD
5
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Approve, in accordance with the NYSE American Company Guide Section 713 and Section 712, the issuance of 12,683,908 shares of common stock in excess of 19.99% of the shares of common stock outstanding as of July 6, 2026 (the “Exchange Cap”), pursuant to outstanding Series D convertible preferred stock and a convertible promissory note in the original principal amount of $576,271 issued on September 18, 2026 which were issued in connection with that certain Exclusive License Agreement dated July 6, 2026.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval is required to issue shares above the Exchange Cap.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Approve, in accordance with the NYSE American Company Guide Section 713 and Section 712, the initial issuance of shares of up to 20,000,000 shares of the Company’s common stock pursuant to that certain securities purchase agreement dated September 19, 2025, as amended (the “ELOC Agreement”) with C/M Capital Master Fund, LP (the “Purchaser”), establishing an equity line of credit pursuant to which the Company may sell shares of common stock to the Purchaser from time to time in its discretion, in excess of and without giving effect to the Exchange Cap.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval is required for the Company to access capital under the amended ELOC Agreement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approve an amendment to our Articles of Incorporation, as amended, to increase the number of the Company’s authorized shares of common stock to 800,000,000 shares.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the amendment would increase authorized common stock to 800,000,000 shares.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approve an amendment to our Articles of Incorporation, as amended, at the discretion of the board of directors, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-49 (1:49), with the exact ratio to be determined by the Board.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the reverse split is intended to maintain compliance with NYSE American minimum bid price requirements.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approve an adjournment of the Special Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the Special Meeting to approve any of the proposals presented for a vote at the Special Meeting.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states adjournment may be needed to solicit additional proxies if votes are insufficient.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

a76e9c7f7ac689c67e1dbf3f4044865d74b55b30044cf99d7fc9f9990c691aee

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates